Syn­cona buys gene ther­a­py com­pa­ny; Ory­zon’s €45M fi­nanc­ing agree­ment; In­Dex scraps PhI­II drug

Syn­cona scoops up Free­line: British life sci­ences in­vestor Syn­cona said Wednes­day it agreed to buy gene ther­a­py mak­er Free­line Ther­a­peu­tics through a new port­fo­lio com­pa­ny. Syn­cona al­ready owns the ma­jor­i­ty of Nas­daq-list­ed Free­line, and it made its ac­qui­si­tion in­ten­tions known last month. — Kyle LaHu­cik

Ory­zon Ge­nomics se­cures €45M in fi­nanc­ing: The com­pa­ny an­nounced Tues­day that it signed a con­vert­ible bond agree­ment with the Swiss in­vest­ment firm Nice & Green for €45 mil­lion, made up of sev­er­al tranch­es of €5 mil­lion each. “In this un­pre­dictable mar­ket sit­u­a­tion, we are ex­cit­ed to have se­cured this fi­nan­cial sup­port,” Ory­zon CEO Car­los Bue­sa said in a news re­lease. Ory­zon ex­pects topline da­ta ear­ly next year for a Phase IIb study of its bor­der­line per­son­al­i­ty dis­or­der treat­ment. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER